Psilocin poisoning and its derivatives
Keywords:
psilocin, 4-AcO-DMT, hallucinogenic mushroomsAbstract
Hallucinogenic mushrooms containing psilocin action and psilocybin has been known for centuries. They belong to the genera: Conocybe, Psylocibe, Gymnophilus and Panaeolus. Psilocin name is derived from Greek and loosely translated means "naked (psilo) head (Cybe)". In many cultures of these fungi were abused during the ritual and mystical rites. Psilocin is used mainly in order to apply the so-called. Tripping, or hallucinogenic pleasurable sensations, mainly in the form of visual hallucinations. However, it can cause side effects in the form of: tachycardia, hypotension, organ damage, and even the occurrence of unwanted "bad Tripping" so-called. "Bad trips". In Poland, despite the ban on their cultivation and use are still popular stimulant mainly among young people. Recently, more popular and more available on the illicit market are their synthetic derivatives. These include, among others 4-Acetoxy-N, N-dimethyltryptamine, known as 4-AcO-DMT. The paper presents the main symptoms of intoxication use and psilocin and its derivatives, as well as the rules of conduct in acute poisonings. Furthermore, a case of a 16-year-old patient hospitalized at the Regional Center of Clinical Toxicology in Lublin due to substance intoxication psychostimulants 4-AcO-DMT.
References
1. Burda P., Ciszowski K. Grzyby trujące. W: Pach J. Zarys toksykologii klinicznej. Kraków 2009. s. 564-9.
2. Janoszka J., Rymkiewicz A., Dobosz T. Halucynogenne grzyby – łasiczki (Psylocibe).Część I. Charakterystyka, skutki zażycia, rozpoznawanie. Arch. Med. Sąd. Krym. 2005; LV: 215-9
3. Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2011 Sep 3. [Epub ahead of print]
4. Samorini G. The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 B.P.). Integration 2/3: 69-78
5. Hofmann A. Teonanácatl and Ololiuqui, two ancient magic drugs of Mexico. UNODC, 1971; Issue 1: 3-14
6. Wojciechowska M. Kambodża. Kobieta na krańcu świata. G+J RBA Wydawnictwo. 2011: 8-40
7. Panasiuk L. Narkotyki i środki halucynogenne. W: Panasiuk L., Król M., Szponar E., Szponar J. Ostre zatrucia. PZWL 2010. s. 144-6.
8. Spoerke DG., Hall AH. Plants and mushrooms of abuse. Emerg Med Clin North Am. 1990; 8(3):579-93.
9. Majewska M., Szponar J., Pyra E., Kostek H., Kujawa A. Zespół serotoninergiczny w przebiegu zatrucia lekami – opis przypadku. Przegląd lekarski, 2011/68/8: 523-526
10. Shen HW., Jiang XL., Winter JC., Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr. Drug Metab, 2010; 11(8): 659-66.
11. Nichols DE. Hallucinogens. Pharmacol Ther. 2004; 101(2): 131-81
12. Gouzoulis-Mayfrank E., Hermle L., Thelen B., Sass H. History, rationale and potential of human experimental hallucinogen drug research in psychiatry. Pharmacopsychiat. 1998; 31: 63-68
13. Benjamin C. Persistent psychiatric symptoms after eating psilocybin mushrooms. British Medical Journal; May: 1319-20.
14. Vollenweider FX., Vontobel P., Hell D., Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11C] raclopride. Neuropsychopharmacology, 1999; 20(5): 424-33
15. Bouso JC., González D., Fondevila S., et all. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS One. 2012; 7(8): e42421.
